Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 59Neoplasm Metastasis 5Prostate Cancer Metastatic 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 3Adenocarcinoma 3Prostate CA 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Urologic Diseases 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stage IV Prostate Adenocarcinoma AJCC v7 1Salivary Gland Neoplasms 1Recurrence 1Radiation Injuries 1Prostatic Diseases 1PSA Level Greater Than 0.03 1Oligometastatic Prostate Cancer 1Neoplasms 1Neoplasm Recurrence, Local 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone-Sensitive Prostate Cance 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Lymphatic Metastasis 1Intraprostatic Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Gastrointestinal Diseases 1

Interventions

olaparib 4Pluvicto 4Abiraterone Acetate 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2enzalutamide 2darolutamide 2Prednisone 2Prednisolone 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1lactitol 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1enfortumab vedotin 1cabozantinib 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × Androgen Antagonists × 1 year × Clear all
NCT07476001 2026-05-15

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
12 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07553988 2026-04-28

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

R-Pharm

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡